Prostate cancer: Can multiparametric mr imaging help identify patients who are candidates for active surveillance?

Radiology

Volumn 268, Issue 1, 2013, Pages 144-152

  Turkbey, Baris ^a   Mani, Haresh ^a   Aras, Omer ^a   Ho, Jennifer ^a   Hoang, Anthony ^a   Rastinehad, Ardeshir R ^a   Agarwal, Harsh ^b   Shah, Vijay ^c   Bernardo, Marcelino ^a,d   Pang, Yuxi ^e   Daar, Dagane ^a,d   McKinney, Yolanda L ^a   Linehan, W Marston ^a   Kaushal, Aradhana ^a   Merino, Maria J ^a   Wood, Bradford J ^a   Pinto, Peter A ^a   Choyke, Peter L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

^c VirtualScopics LLC   (United States)

^d SAIC FREDERICK INC   (United States)

^e PHILIPS HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER OF THE PROSTATE RISK ASSESSMENT SCORING SYSTEM; D'AMICO SCORING SYSTEM; EPSTEIN SCORING SYSTEM; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

EID: 84879958893     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13121325     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29.
3. Lilja H, Ulmert D, Vickers AJ. Prostatespecific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8(4):268-278.
4. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-1328.
5. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004;22(11):2141-2149.
6. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94(13):981-990.
7. Seiler D, Randazzo M, Klotz L, et al. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort. BJU Int 2012;110(2): 195-200.
8. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178(6):2359-2364; discussion 2364-2365.
9. van den Bergh RC, Roemeling S, Roobol MJ, et al. Outcomes of men with screendetected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009;55(1):1-8.
10. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29(16):2185-2190.
11. Bastian PJ, Carter BH, Bjartell A, et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009;55(6):1321-1330.
12. Suardi N, Capitanio U, Chun FK, et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 2008;113(8):2068-2072.
13. Lee MC, Dong F, Stephenson AJ, Jones JS, Magi-Galluzzi C, Klein EA. The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy. Eur Urol 2010;58(1):90-95.
14. Hekal IA, El-Tabey NA, Nabeeh MA, et al. Validation of Epstein criteria of insignificant prostate cancer in Middle East patients. Int Urol Nephrol 2010;42(3):667-671.
15. Behbahani TE, Ellinger J, Caratozzolo DG, Müller SC. Pathological outcomes of men eligible for active surveillance after undergoing radical prostatectomy: are results predictable? Clin Genitourin Cancer 2012;10(1):32-36.
16. Shukla-Dave A, Hricak H, Akin O, et al. Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int 2012;109(9):1315-1322.
17. Ploussard G, Salomon L, Xylinas E, et al. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance: does the risk of misclassification vary according to biopsy criteria? J Urol 2010;183(2):539-544.
18. Turkbey B, Mani H, Shah V, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011;186(5):1818-1824.
19. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 2010;255(1): 89-99.
20. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281(15):1395-1400.
21. Duffield AS, Lee TK, Miyamoto H, Carter HB, Epstein JI. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol 2009;182(5):2274-2278.
22. Rice KR, Colombo ML, Wingate J, et al. Low risk prostate cancer in men ? 70 years old: to treat or not to treat. Urol Oncol 2011 Aug 25. [Epub ahead of print]
23. O'Brien D, Loeb S, Carvalhal GF, et al. Delay of surgery in men with low risk prostate cancer. J Urol 2011;185(6):2143-2147.
24. Suardi N, Briganti A, Gallina A, et al. Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. BJU Int 2010;105(11):1548-1552.
25. Guzzo TJ, Resnick MJ, Canter DJ, et al. Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance. Urol Oncol 2012;30(3):301-305.
26. Silberstein JL, Vickers AJ, Power NE, et al. Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer 2011;117(21):4855-4860.
27. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22(4):746-757.